Based on previous findings, we concluded that targeted next-generation sequencing is a useful tool to detect DNA mutations that could have clinical utility in predicting response to anti-HER2-targeted therapy allowing individualized treatment regimens for HER2-positive breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.